

**Food and Drug Administration (FDA)**  
**Center for Drug Evaluation and Research (CDER)**  
*Joint Meeting of the Advisory Committee for Reproductive Health Drugs (ACRHD) and the  
Drug Safety and Risk Management Advisory Committee (DSaRM)*

FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center  
(Rm. 1503), Silver Spring, MD  
**March 5, 2013**

**MEETING ROSTER**

---

**DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Kalyani Bhatt, BS, MS**

Division of Advisory Committee and  
Consultant Management  
Office of Executive Programs, CDER, FDA

**ADVISORY COMMITTEE FOR REPRODUCTIVE HEALTH DRUGS MEMBERS (Voting)**

**Richard Bockman, MD, PhD**

Head, Endocrine Service  
The Hospital for Special  
Surgery  
New York, New York

**Toby Chai, MD**

Vice Chair of Research  
Co-Director of Female Pelvic Medicine and  
Reconstructive Surgery Program  
Department of Urology  
Yale School of Medicine  
New Haven, Connecticut

**Bart Clarke, MD**

Associate Professor of Medicine  
Mayo Clinic College of Medicine  
Department of Medicine, Endocrinology,  
Diabetes, Metabolism and Nutrition  
Rochester, Minnesota

**Kathryn M. Curtis, PhD**

Women's Health and Fertility Branch  
Division of Reproductive Health  
Centers for Disease Control and Prevention  
Atlanta, Georgia

**Julia V. Johnson, MD**

*(Chairperson)*

Professor and Chair  
Department of Obstetrics and Gynecology  
University of Massachusetts Medical School  
Worcester, Massachusetts

**John Kittelson, PhD**

Department of Biostatistics and Informatics  
University of Colorado Denver  
Aurora, Colorado

**Michele J. Orza, ScD**

*(Consumer Representative)*

Senior Advisor to the Executive Director  
Patient-Centered Outcomes Research Institute  
Washington, District of Columbia

**Clifford J. Rosen, MD**

Director of Clinical and Translational Research  
Maine Medical Center Research Institute  
Scarborough, Maine

**Amy Whitaker, MD, MS**

Assistant Professor  
The University of Chicago  
Department of Obstetrics and Gynecology  
Section of Family Planning and Contraceptive  
Research  
Chicago, Illinois

**Food and Drug Administration (FDA)**  
**Center for Drug Evaluation and Research (CDER)**  
*Joint Meeting of the Advisory Committee for Reproductive Health Drugs (ACRHD) and the  
Drug Safety and Risk Management Advisory Committee (DSaRM)*

**March 5, 2013**

**MEETING ROSTER (cont.)**

---

**ADVISORY COMMITTEE FOR REPRODUCTIVE HEALTH DRUGS MEMBER (Non-Voting)**

**Keith Gordon, PhD**

*(Industry Representative)*

Regional Director Medical Affairs Women's  
Health & Endocrine, USA  
Merck & Company  
Whitehouse Station, New Jersey

**DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBERS (Voting)**

**William Cooper, MD**

Professor of Pediatrics and Preventive Medicine  
Vanderbilt University School of Medicine  
Nashville, Tennessee

**David Madigan, PhD**

Professor, Chair  
Department of Statistics  
Columbia University

**Marjorie Shaw Phillips, MS, RPh, FASHP**

Pharmacy Coordinator  
Clinical Research and Education  
Georgia Health Sciences Health System  
Augusta, Georgia

**Maria Saurez-Almazor, MD, PhD**

Barnts Family Distinguished Professor  
University of Texas MD Anderson Cancer  
Center  
Houston, Texas

**Almut Winterstein, PhD**

Professor and Graduate Program Director  
Pharmaceutical Outcomes & Policy  
College of Pharmacy  
Epidemiology, College of Public Health and  
Health Professions and College of Medicine  
University of Florida  
Gainesville, Florida

**T. Mark Woods, PharmD**

Clinical Coordinator and Residency Program  
Director  
Pharmacy Department  
Saint Luke's Hospital  
Kansas City, Missouri

**Food and Drug Administration (FDA)**  
**Center for Drug Evaluation and Research (CDER)**  
*Joint Meeting of the Advisory Committee for Reproductive Health Drugs (ACRHD) and the  
Drug Safety and Risk Management Advisory Committee (DSaRM)*

**March 5, 2013**

**MEETING ROSTER (cont.)**

---

**DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBER (Non-Voting)**

**Patrizia Cavazzoni, M.D.**

*(Industry Representative)*

Senior Vice President - Worldwide Safety Strategy  
Pfizer, Inc  
New York, New York

**TEMPORARY MEMBERS (Voting)**

**Diane M. Biskobing, MD**

Associate Professor of Medicine  
Virginia Commonwealth University School of  
Medicine  
Department of Internal Medicine;  
Endocrinology and Metabolism  
Richmond, Virginia

**Kenneth Burman, MD**

Chief, Endocrine Section  
Washington Hospital Center  
Washington, District of Columbia

**Michael Collins, MD**

Chief, Skeletal Clinical Studies Unit  
National Institutes of Health  
Bethesda, Maryland

**Natalie Compagni Portis, PsyD**

*(Patient Representative)*

Oakland, California

**Mary D. Ruppe, MD**

Program Director Endocrinology Fellowship  
The Methodist Hospital  
Houston, Texas

**Thomas Weber, MD**

Associate Professor of Medicine  
Duke University Medical Center  
Durham, North Carolina

**Food and Drug Administration (FDA)**  
**Center for Drug Evaluation and Research (CDER)**  
*Joint Meeting of the Advisory Committee for Reproductive Health Drugs (ACRHD) and the  
Drug Safety and Risk Management Advisory Committee (DSaRM)*

**March 5, 2013**

**MEETING ROSTER (cont.)**

---

**FDA PARTICIPANTS (Non-Voting)**

**Hylton Joffe, MD, MMSc**

Director  
Division of Reproductive and Urologic Products  
(DRUP)  
Office of Drug Evaluation III (ODE III), Office  
of New Drugs (OND), CDER, FDA

**Rita Ouellet-Hellstrom, PhD, MPH**

Associate Director for Epidemiology  
Division of Epidemiology II  
Office of Surveillance and Epidemiology (OSE),  
CDER, FDA

**Theresa Kehoe, MD**

Clinical Team Leader  
DRUP, ODEIII, OND, CDER, FDA

**Stephen Voss, MD**

Medical Officer  
DRUP, ODEIII, OND, CDER, FDA

**CDR David Moeny, RPh, MPH, USPHS**

Epidemiologist  
Division of Epidemiology II  
OSE, CDER, FDA

**Janelle Charles, PhD**

Mathematical Statistician  
Division of Biometrics VII  
Office of Biostatistics  
Office of Translational Sciences  
CDER, FDA